Philip Kantoff, MD

About Philip Kantoff, MD

Philip Kantoff, MD received his undergraduate degree and medical degree from Brown University, and was chief resident in Internal Medicine at New York University Hospital/Bellevue Hospital. He spent four years at the National Institutes of Health conducting research in retroviral mediated gene transfer and gene therapy. He completed his medical oncology fellowship training at the Dana-Farber Cancer Institute (DFCI) in 1987. Dr. Kantoff currently serves as the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). As Chairman of the Department of Medicine at MSKCC, he oversees a department of over 400 physicians and physician scientists who care for cancer patients and the development and testing of better cancer therapies. Before coming to MSKCC, Dr. Kantoff was the Jerome and Nancy Kohlberg Chair at Harvard Medical School and served as Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. Dr. Kantoff focuses his clinical activities in caring for patients with prostate and testicular cancers. His research is both clinical and translational. His clinical research involves developing improved treatments for patients with genitourinary cancers. His laboratory efforts involve understanding the molecular basis of prostate cancer including mechanisms of resistance to Hormonal Therapy and genetic determinants of aggressive disease. As Chairman of the Prostate Cancer Foundation’s (PCF) Global Research Council (GRC), Dr. Kantoff advises the leadership of PCF on a wide variety of matters concerning scientific program policy and progress and future direction of the PCF’s research programs and research enterprise in the areas of basic, translational, clinical science and epidemiology. As Chairman of the GRC, Dr. Kantoff leads the GRC members in generating its independent advice to PCF.